Accelerate Diagnostics Announces Completion Of Its WAVE Pre-Clinical Trial Designed To Deliver Rapid Antimicrobial Susceptibility Testing Directly From Positive Blood Culture Bottles And Bacterial Isolated Colonies To Report Accurate Results Within 4.5 Hours, On Average
Portfolio Pulse from Benzinga Newsdesk
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced the successful completion of its WAVE pre-clinical trial, which aims to deliver rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolated colonies. The WAVE system can report accurate results within 4.5 hours, potentially improving patient outcomes, reducing hospital costs, and combating antimicrobial resistance.
August 08, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has completed its WAVE pre-clinical trial, which aims to deliver rapid antimicrobial susceptibility testing (AST) within 4.5 hours. This development could significantly impact patient outcomes, hospital costs, and antimicrobial resistance.
The successful completion of the WAVE pre-clinical trial is a significant milestone for AXDX. The ability to deliver rapid AST results can improve patient outcomes, reduce hospital costs, and combat antimicrobial resistance, which are critical factors in the healthcare industry. This positive development is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100